MedTrace Logo

Long-term Study of SYR-472

NCT01431807 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 680

Last updated 2023-12-14

No results posted yet for this study

Summary

To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.

Conditions

Interventions

DRUG

SYR-472

oral, for up to 52 weeks.

Sponsors & Collaborators

Principal Investigators

  • Senior Director · Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-01
Primary Completion
2013-06-01
Completion
2013-06-01

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01431807 on ClinicalTrials.gov